E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
NCT02279394
Completed
This research study is aimed to determine the proportion of high risk smoldering multiple myeloma patients who are progression free at 2 years after receiving elotuzumab, lenalidomide and dexamethasone combination therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2023
Locations: Colorado Blood Cancer Institute, Denver, Colorado +8 locations
Conditions: Smoldering Myeloma, Smoldering Multiple Myeloma
Register for Updates
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
NCT01728259
Terminated
This phase I trial studies the side effects and best dose of pomalidomide and bortezomib when given together with dexamethasone in treating patients with amyloid light-chain amyloidosis or light chain deposition disease. Biological therapies, such as pomalidomide, may stimulate the immune system in different ways and stop abnormal cells from growing. Bortezomib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth. Giving pomalidomide and bortezomib togethe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2023
Locations: Colorado Blood Cancer Institute, Denver, Colorado +4 locations
Conditions: Light Chain Deposition Disease, Primary Systemic Amyloidosis
Register for Updates
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer
NCT01698918
Completed
The purpose of this study was to assess the efficacy and safety of first-line treatment with everolimus plus letrozole in postmenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer. Moreover, the study also aimed to investigate the efficacy and safety of second line treatment with everolumus plus examestane in participants whose disease progressed during everolimus plus letrozole therapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/28/2023
Locations: University of Alabama Comprehensive Cancer Center SC-2, Birmingham, Alabama +51 locations
Conditions: Hormone Receptor Positive Breast Cancer
Register for Updates
Intraoperative Methadone Administration for Improved Pain Control in Spinal Fusion Patients
NCT02989597
Terminated
Methadone has several advantages over standard narcotic medications, especially when considering use after a typically painful surgery such as lumbar fusion. Methadone is low cost, has a long half-life, has a convenient dosing schedule, has excellent oral bioavailability, and demonstrates slow onset to withdrawal. The literature comparing methadone to more commonly used post-operative narcotics demonstrates that it manages pain better, sustains consistent plasma concentrations, decreases overall... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/24/2023
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Pain, Postoperative
Register for Updates
Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
NCT03330028
Completed
The goal of this clinical research study is to find the highest tolerable dose of paclitaxel that can be given as hyperthermic intraperitoneal chemotherapy (HIPEC) to patients with gastric or gastroesophageal cancer. HIPEC is a system in which heated chemotherapy is delivered directly inside the abdomen during surgery. In this study, paclitaxel is being combined with mitomycin and cisplatin to see if this study drug combination can help to control the disease. This is an investigational study.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/20/2023
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Diseases of Oesophagus Stomach and Duodenum
Register for Updates
Dexamethasone and COVID-19 Inpatient Mortality
NCT04926571
Completed
The study aims to assess the effectiveness of dexamethasone initiation to reduce the risk of inpatient mortality within 28 days among US patients hospitalized with COVID-19 diagnosis or SARS-CoV-2 infection, overall and stratified by COVID-19 severity subgroups.
Gender:
ALL
Ages:
All
Trial Updated:
04/13/2023
Locations: Aetion, Inc., New York, New York
Conditions: Coronavirus
Register for Updates
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
NCT03465540
Terminated
Evaluate the safety and tolerability of AMG 397. Estimate the maximum tolerated doses (MTDs) and/or biologically active doses.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/06/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama +20 locations
Conditions: Multiple Myeloma, Acute Myeloid Leukemia, AML, NHL, Non-Hodgkins Lymphoma, Myelodysplastic Syndrome, MDS
Register for Updates
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
NCT00005585
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which regimen of combination chemotherapy is more effective for childhood acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is comparing different regimens of combination chemotherapy to see how well they work in treating children with acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 1 year and 9 years
Trial Updated:
04/04/2023
Locations: Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama +122 locations
Conditions: Leukemia
Register for Updates
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00005596
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which regimen of chemotherapy is more effective for acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is comparing four regimens of combination chemotherapy to see how well they work in treating children with newly diagnosed acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
04/04/2023
Locations: Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama +122 locations
Conditions: Leukemia
Register for Updates
Use of Dexamethasone in Pediatric Asthma Exacerbations
NCT02192827
Completed
The purpose of this study is to compare the efficacy of a single dose of dexamethasone vs. two doses of dexamethasone in mild and moderate asthma exacerbations pediatric patients.
Gender:
ALL
Ages:
Between 2 years and 20 years
Trial Updated:
03/29/2023
Locations: Women and Children's Hospital Of Buffalo, Buffalo, New York
Conditions: Asthma
Register for Updates
Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
NCT03411031
Terminated
The purpose of this study is determine Time-to-Progression with elotuzumab plus lenalidomide when elotuzumab is added to multiple myeloma participants with serologic relapse/progression while receiving lenalidomide maintenance for each study arm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2023
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Multiple Myeloma
Register for Updates
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
NCT00783367
Completed
Pre-clinical data and recently published clinical data suggest a synergistic effect between lenalidomide and dexamethasone. We hypothesize that a combination of lenalidomide-dexamethasone can overcome rituximab resistance. To determine the response rate to lenalidomide and dexamethasone plus rituximab therapy in subjects with recurrent small B-cell non-Hodgkin lymphoma who have had lymphoma progression within 6 months of being treated with rituximab alone or with a rituximab-containing regimen,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2023
Locations: University of Pennsylvania; Abramson Cancer Center; Lymphoma Program, Philadelphia, Pennsylvania
Conditions: Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, MALT Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue, Lymphoma, Small Lymphocytic, Waldenstrom Macroglobulinemia, Mantle-Cell Lymphoma
Register for Updates